3D Systems (DDD) Q4 2024 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2024 earnings summary
1 Dec, 2025Executive summary
Full-year 2024 revenue reached $440 million, meeting expectations despite a $9 million Q4 reduction from a change in accounting estimate for the Regenerative Medicine program.
Strong Q4 industrial printer sales and global services growth, with Application Innovation Group revenues up 18% for FY'24.
Announced cost reduction and profitability plan targeting over $50 million in annualized savings by mid-2026, with 10% already implemented.
Insourcing and supply chain actions implemented for quality, delivery, and cost control.
Announced sale of Geomagic software platform for $123 million, expected to close in early Q2 2025, with proceeds to strengthen liquidity.
Financial highlights
Q4 2024 consolidated revenue was $111 million, down 3% year-over-year, mainly due to the $9 million accounting change.
Full-year 2024 revenue was $440 million, down 10% from 2023, with industrial solutions at $250 million (down 9%) and healthcare solutions at $190 million (down 11%).
Q4 non-GAAP gross margin was 31.3% (down from 39.8% prior year); full-year non-GAAP gross margin was 37.4% (down from 40.6%).
Q4 adjusted EBITDA was negative $19.1 million; full-year adjusted EBITDA was negative $66.4 million.
Ended 2024 with $171 million in cash and cash equivalents, down from $332 million in 2023, mainly due to debt repurchases.
Outlook and guidance
2025 revenue guidance is $420–$435 million, representing flat to modest growth after excluding Geomagic revenue.
Non-GAAP gross margin expected in the 37–39% range, with operating expenses of $200–$220 million.
Adjusted EBITDA expected to improve each quarter in 2025, with break-even or better by Q4.
Cost reduction and restructuring actions targeting over $50 million in annualized savings by mid-2026, with 10% already implemented.
Macro and geopolitical uncertainty expected to persist, impacting top-line growth.
Latest events from 3D Systems
- Q4 2025 saw 16% sequential growth, margin gains, and $55M in cost savings, led by key segments.DDD
Q4 20259 Mar 2026 - Q2 revenue rose sequentially, margin improved, and full-year outlook targets breakeven Q4.DDD
Q2 202422 Jan 2026 - FDA-approved 3D printed dentures and aerospace growth position the business for major expansion.DDD
28th Annual Needham Growth Conference Virtual13 Jan 2026 - Q3 revenue fell 9% YoY to $112.9M, with a $178.6M net loss from impairment charges.DDD
Q3 202412 Jan 2026 - Aggressive cost actions and R&D focus position the business for growth in key markets.DDD
27th Annual Needham Growth Conference10 Jan 2026 - Dental and healthcare 3D printing lead growth, with cost control and new products driving profitability.DDD
Cantor Fitzgerald Global Technology Conference26 Dec 2025 - Annual meeting to vote on directors, pay, incentive plan, and auditor, with focus on ESG and governance.DDD
Proxy Filing1 Dec 2025 - Shareholders to vote on key proposals as leadership addresses internal control remediation.DDD
Proxy Filing1 Dec 2025 - Virtual annual meeting to elect nine directors, approve pay, and ratify auditor on May 16, 2025.DDD
Proxy Filing1 Dec 2025